Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Ticagrelor boosts aspirin in patients with diabetes, prior PCI, stable CAD

30 Sep 2019

The addition of ticagrelor to aspirin leads to better outcomes in patients with diabetes, previous percutaneous coronary intervention (PCI) and stable coronary artery disease (CAD), a recent study has found. The combination may also increase the risk of major bleeding, however.

Researchers randomly assigned 11,154 patients with previous PCI to receive either ticagrelor or placebo. The primary efficacy outcome was the composite of cardiovascular death, stroke or myocardial infarction.

Over a median follow-up of 3.3 years, 404 episodes (7.3 percent) of the primary outcome were reported in the ticagrelor group. This was significantly lower than that in the placebo group, in which 480 such episodes (8.6 percent) were documented (hazard ratio [HR], 0.85, 95 percent CI, 0.74–0.97; p=0.013).

In a separate analysis involving patients with no prior PCI, add-on ticagrelor did not yield such a benefit (8.2 percent vs 8.4 percent; HR, 0.98. 0.84–1.14; p=0.76).

The occurrence of ST-elevation myocardial infarction was also significantly suppressed in those who received ticagrelor (0.3 percent vs 0.9 percent; HR, 0.32, 0.18–0.55; p<0.0001). The same was true for another composite endpoint consisting of coronary, cerebral and peripheral ischaemic events.

On the other hand, major bleeding, according to the Thrombolysis in Myocardial Infarction (TIMI; HR, 2.03, 1.48–2.76; p<0.0001) and Platelet Inhibition and Patient Outcomes (PLATO; HR, 2.22, 1.72–2.86; p<0.0001) criteria, was significantly increased in those who were given ticagrelor.

This effect remained true even in those without a history of PCI (TIMI: HR, 2.79, 1.91–4.06; p<0.0001; PLATO: HR, 2.72, 1.99–3.72; p<0.0001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.